"We Envision Growth Strategies Most Suited
to Your Business"
The global immunology market size stood at USD 102.41 billion in 2022. The market value is poised to rise from USD 97.58 billion in 2023 to USD 194.28 billion by 2030 at a CAGR of 10.3% during 2023-2030.
Fortune Business Insights™ presents this information in its report titled “Immunology Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Monoclonal Antibody (mAb), Fusion Proteins, Immunosuppressants, and Others), By Disease Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2023-2030”.
Immunology drugs or agents modify the immune system's response, enhancing it to combat infections or suppressing it to treat immunological or autoimmune disorders such as rheumatoid arthritis and psoriatic arthritis. The increasing awareness pertaining to immunological diseases, spanning both developed and developing nations, is a driving force behind the growing demand for immunological drugs and treatments.
Impact of the COVID-19 Pandemic on Revenues Led to Slower Market Growth
The COVID-19 pandemic caused revenue decline for some market players, such as Merck & Co., Inc., leading to slower global market growth during 2019-2020. The disruption caused by the pandemic affected sales and operations. Moreover, regulatory delays for drug approvals, patent expirations, increased biosimilar use during the outbreak, and disrupted patient healthcare visits contributed to slower market expansion.
AbbVie collaborated and Signed an Option-To-License Agreement with HotSpot Therapeutics, Inc. for the Autoimmune Diseases Treatments
In December 2022, AbbVie entered into an exclusive global collaboration and option to license agreement with HotSpot Therapeutics, Inc. This strategic partnership encompassed HotSpot's early-stage IRF5 program, dedicated to developing therapies for autoimmune diseases and cancer.
Growing Occurrence of Autoimmune Diseases to Spur Market Progress
The rise in awareness regarding autoimmune diseases, observed in both developed and developing regions, is pivotal in driving market growth. As more people and healthcare providers recognize these conditions, higher demand for immunological drugs and treatments drives market growth. Moreover, the significant expansion of drug development portfolios by key industry players, such as Sanofi and Johnson & Johnson Services, Inc., with numerous projects and candidates targeting autoimmune indications, is another factor promoting market growth.
However, the substantial expenses associated with research and development, drug manufacturing, and clinical trials could hinder immunology market growth.
Key Players Strike Partnership to Solidify their Market Positions
The current market landscape exhibits consolidation, characterized by major players such as Janssen Global Services, LLC, Amgen, Pfizer, Novartis AG, and AbbVie Inc. These industry participants strongly focus on pharmaceutical research and development, strategically acquiring domestic firms to solidify their position.
List of Key Players Profiled in the Report:
To get a detailed report summary and research scope of this market, click here:
Key Industry Development
Further Report Findings
Table of Segmentation
CAGR of 10.3% from 2023-2030
Value (USD Billion)
By Drug Class
By Disease Indication
By Distribution Channel